Generic Iloprost Trometamol

Our Principal
Karmed, an Austrian-based prostaglandin specialised pharmaceutical development company has successfully developed several generic injectable prostaglandin products for treatment of various critical diseases.

Product Opportunity - Iloprost Trometamol
Following the originator’s patent expiry (Ilomedin®), a generic registration dossier is available for registration submission. This generic Iloprost Trometamol is available for exclusive licensing for the following territories:
- Middle East
- Turkey
- Asia (excluding Taiwan)

Generic Iloprost Trometamol has been licensed out at an exclusive basis for EU27, Turkey and Former CIS countries however, exclusive licensing opportunities are still available for:
- UK
- Ireland
- Belgium
- Netherlands
- Spain

National authorization has been submitted and is on-going in France whilst MRP is on-going in Austria.

The Product – Iloprost Trometamol
A form of prostacyclin, belonging to a group of agents in the body called prostaglandins. The product is indicated for the treatment of:
- Peripheral Arterial Occlusive Disease (PAOD)
- Buerger’s disease
- Severe disabling Raynaud’s phenomenon.

The product is made available in a formulation of 20mcg/ml identical to the originator’s product.

The Offering
This offering is likely to appeal to generic companies wishing to expand their presence and revenues within the hospital critical care franchise. Exclusive licensing rights can be obtained at commercial terms which include a Licensing Fee (Milestone Payments) and Royalty Payments. Karmed could either:
- secure the supply of finished manufactured goods at conditions where COGS is approximately 25-30% of Licensee’s obtained selling price OR
- sell dossier to interested parties at a once off fee where after the licensee will handle manufacturing/ supply on its own

Bona fide interested parties wishing to pursue this opportunity should communicate directly with one of the persons detailed hereunder. Confidential Information will be released subject to execution of a Confidential Disclosure Agreement.